Search

everythinglearnresearchcommunity

for

Search:↓

The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.

Alopecia areata causes hair loss, has no cure, and various treatments exist.

Asia has made significant progress in tissue engineering and regenerative medicine, but wider clinical use requires more development.

COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.

Lichen planopilaris is a chronic, scarring hair loss condition with no definitive cure, requiring accurate diagnosis and treatment to manage symptoms.

Alopecia Areata is an autoimmune condition often starting before age 20, with varied treatment success and a need for personalized treatment plans.

Some treatments, like corticosteroids and sensitizing agents, can help with alopecia areata, but more high-quality research is needed.

Advanced nanocarrier and microneedle drug delivery methods are more effective, safer, and less invasive for treating skin diseases.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Nanoparticulate systems improve drug delivery by controlling release, protecting drugs, changing absorption and distribution, and concentrating drugs in targeted areas.

New alopecia treatments aim for better results and fewer side effects.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

The conclusion is that we need more effective hair loss treatments than the current ones, and these could include new drugs, gene and stem cell therapy, hormones, and scalp cooling, but they all need thorough safety testing.

Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.

Rituximab leads to longer remission and fewer side effects than cyclophosphamide.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

Patients with chronic skin conditions on systemic treatments did not have worse COVID-19 outcomes and could resume their treatments after recovery.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Acitretin is effective for severe psoriasis and can be used long-term due to no immunosuppression, but must be carefully monitored for side effects and is not for pregnant women.

Methotrexate effectively treated a 2-year-old's generalized pustular psoriasis without side effects.

The document concludes that eyelash trichomegaly, which is the abnormal growth of eyelashes, can be present from birth, caused by diseases, or result from certain medications.

An 8-year-old girl with vitiligo developed extra hair growth on her knee after using tacrolimus ointment.

There is no standard treatment for the rare Cronkhite–Canada syndrome, which can be fatal and lead to cancer.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

A 10-year-old girl with Fox Fordyce disease improved with treatment, suggesting the disease can occur before puberty and might be underdiagnosed in young girls.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

UVA1-light therapy successfully treated a child's skin condition, mycosis fungoides.

Women with Systemic Lupus Erythematosus should have closely monitored pregnancies and avoid certain medications to improve their pregnancy outcomes.

Fox Fordyce disease might be more common in prepubertal girls than thought and can be managed with treatment.